Pathophysiology and clinical importance of hyperhomocysteinemia: Clinical intervention studies

Mineral and Electrolyte Metabolism

Volumn 25, Issue 4-6, 1999, Pages 286-290

  Sunder Plassmann, Gere ^a   Födinger, Manuela ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Arteriosclerosis; Atherosclerosis; Cardiovascular disease; Folic acid; Hemodialysis; Hyperhomocysteinemia; Kidney transplantation; Morbidity; Mortality; Peritoneal dialysis; Total Homocysteine; Vitamin B12; Vitamin B6

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PLACEBO; PYRIDOXINE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 0343339989     PISSN: 03780392     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057461     Document Type: Article

References (31)

1. McCully KS: Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-128.
2. McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. Atherosclerosis 1975;22:215-227.
3. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Grobe H, Schmidt H, Schweitzer L: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985;37: 1-31.
4. Mudd SH, Levy HL, Skovby F: Disorders of transulfuration; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Basis of Inherited Disease, ed 7, vol 1, McGraw-Hill, New York, 1995, pp 1279-1327.
5. Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. Annu Rev Medicine 1998;49:31-62.
6. Clarkc R: Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomized trials. Br Med J 1998;316:894-898.
7. Peterson JC, Spence JD: Vitamins and progression of atherosclerosis in hyperhomocyst(e)inacmia (letter). Lancet 1998;351:263.
8. Verhaar MC, Wever RMF, Kastelein JJP, Van Dam T, Koomans HA, Rabelink TJ: 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998;97:237-241.
9. Wilcken DEL: MTHFR 677C-T mutation, folate intake, neural-tube defect, and risk of cardiovascular disease. Lancet 1997;350:603-604.
10. Food and Drug Administration: Food standards: Amendment of standards of identity for enriched grain products to require addition of folic acid. Fed Regist 1996;61:8781-8797.
11. Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM: Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338: 1009-1015.
12. Oakley GP: Plasma homocyst(e)ine levels and folic acid supplementation (letter). N Engl J Med 1998;339:476-477.
13. Oakley GP: Eat right and take a multivitamin. N Engl J Med 1998;338:1060-1061.
14. Omenn GS, Beresford SAA, Motulsky AG: Preventing coronary heart disease. B vitamins and homocysteine Circulation 1998;97:421-424.
15. McCully KS: Homocysteine, folate, vitamin B6 and cardiovascular disease. JAMA 1998;279: 392-393.
16. Kuller LH, Evans RW: Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98: 196-199.
17. Rafael Perez-Escamilla: Plasma homocysteine levels and folic acid supplementation (letter). N Engl J Med 1998;339:475-476.
18. Suliman ME, Anderstam B, Lindholm B, Bergström J: Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 1997;12:2332-2338.
19. Hultberg B, Andersson A, Sterner G: Plasma homocysteine in renal failure. Clin Nephrol 1993;40:230-234.
20. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, Hörl WH, Sunder-Plassman G: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 1997;52:517-523.
21. Vychytil A, Födinger M, Wölfl G, Enzenberger B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter CH, Hörl WH, Sunder-Plassman G: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 1998;53:1775-1782.
22. Vychytil A, Födinger M, Papagiannopoulos M, Wölfl G, Hörl WH, Sunder-Plassmann G: Peritoneal elimination of total homocysteine moieties in continuous ambulatory peritoneal dialysis patients. Kidney Int 1999;55:2054-2061.
23. Födinger M, Wölfl G, Fischer G, Rasoul-Rockenschaub S, Schmid R, Hörl WH, Sunder-Plassmann G: Effect of MTH FR 677C → T on plasma total homocysteine levels in renal graft recipients. Kidney Int 1999;55:1072-1080.
24. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implications for prevention of vascular disease. Metabolism 1988;37:697-701.
25. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996;49:147-152.
26. Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jaques PF, Selhub J, Rosenberg IH: Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997;127: 1089-1092.
27. Dierkes J, Domröse U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 1999;51:108-115.
28. Perna AF, Ingrosso D, DeSanto NG, Galletti P, Brunone M, Zappia V: Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia. J Am Soc Nephrol 1997;8:1899-1905.
29. Van Guldener C, Janssen MJFM, Lambert J, Ter Wee PM, Jakobs C, Donker AJM, Stehouwer CDA: No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant 1998;13:106-112.
30. Kunz K, Petitjean P, Lisri M, Chantrel F, Koehl C, Wiesel ML, Cazenave JP, Moulin B, Hannedouche TP: Cardiovascular morbidity and endothelial dysfunction in chronic hemodialysis patients: Is homocyst(e)ine the missing link? Nephrol Dial Transplant 1999;14:1934-1942.
31. Yeun JY: The role of homocysteine in end-stage renal disease. Seminars Dial 1998;11:95-101.